Health Outcomes of 215 Mothers of Children With Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry.

anti-SSA/Ro antibodies congenital heart block maternal diseases neonatal lupus erythematosus syndrome pregnancy systemic lupus erythematosus

Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
Oct 2022
Historique:
accepted: 20 05 2022
pubmed: 3 5 2022
medline: 26 10 2022
entrez: 2 5 2022
Statut: ppublish

Résumé

Transplacental passage of maternal anti-SSA and anti-SSB antibodies, potentially associated with maternal autoimmune diseases, can cause neonatal lupus syndrome. Given the paucity of data in this setting, we report short- and long-term outcomes of mothers of offspring with congenital heart block (CHB). This retrospective study included anti-SSA/SSB antibody-positive mothers of fetuses with high-degree CHB and focused on their health status before pregnancy, at CHB diagnosis, and thereafter. We analyzed 215 women with at least 1 pregnancy with CHB. Prior to this diagnosis, only 52 (24%) mothers had been diagnosed with an autoimmune disease, mainly systemic lupus erythematosus (SLE; n = 26, 12%) and Sjögren syndrome (SS; n = 16, 7%). Six more were diagnosed with an autoimmune disease during the index pregnancy. Of the 157 mothers (73%) with no such diagnosis at childbirth, 77 (49%) developed one after a median follow-up of 11 years (range: 21 days to 54 years). By the end of follow-up, 135 women (63%) had an autoimmune disease diagnosis, mainly SLE (n = 54, 25%) and SS (n = 72, 33%). Three patients with SLE had renal involvement, and only 6 (3%) had required an immunosuppressive drug at any point. The symptoms best predicting autoimmune disease development were arthralgia and myalgia ( One-quarter of the patients had an autoimmune disease diagnosis at the time of the fetal CHB diagnosis. Nearly half of those without an initial diagnosis progressed during follow-up, most without severe manifestations. Severe diseases such as lupus nephritis were rarely seen, and immunosuppressive drugs were rarely required.

Identifiants

pubmed: 35501147
pii: jrheum.210703
doi: 10.3899/jrheum.210703
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1124-1130

Informations de copyright

Copyright © 2022 by the Journal of Rheumatology.

Auteurs

Imene Miniaoui (I)

I. Miniaoui, MD, N. Morel, MD, K. Lévesque, MD, G. Guettrot-Imbert, MD, V. Le Guern, MD, L. Mouthon, MD, PhD, M. Jallouli, MD, AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris.

Nathalie Morel (N)

I. Miniaoui, MD, N. Morel, MD, K. Lévesque, MD, G. Guettrot-Imbert, MD, V. Le Guern, MD, L. Mouthon, MD, PhD, M. Jallouli, MD, AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris.

Kateri Lévesque (K)

I. Miniaoui, MD, N. Morel, MD, K. Lévesque, MD, G. Guettrot-Imbert, MD, V. Le Guern, MD, L. Mouthon, MD, PhD, M. Jallouli, MD, AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris.

Alice Maltret (A)

A. Maltret, MD, J. Le Bidois, MD, D. Bonnet, MD, PhD, AP-HP, Centre de référence Malformations Cardiaques Congénitales Complexes - M3C, Hôpital Necker-Enfants malades, Université de Paris, Paris.

Marine Driessen (M)

M. Driessen, MD, Obstetrics and materno-fœtal unit, AP-HP Hôpital Necker-Enfant Malades, Université de Paris, Paris.

Agathe Masseau (A)

A. Masseau, MD, Service de Médecine Interne, CHU Nantes.

Pauline Orquevaux (P)

P. Orquevaux, MD, CHU de Reims, Centre de compétence maladies auto-immunes et systémiques rares, Reims.

Jean-Charles Piette (JC)

J.C. Piette, MD, PhD, Université Pierre et Marie Curie, AP-HP, Hôpital Pitié-Salpêtrière, Centre de référence maladies auto-immunes et systémiques rares, Paris.

Francois Barriere (F)

F. Barriere, MD, AP-HM, Hôpital Timone Enfants, Unité de Réanimation Pédiatrique, Marseille.

Jérome Le Bidois (J)

A. Maltret, MD, J. Le Bidois, MD, D. Bonnet, MD, PhD, AP-HP, Centre de référence Malformations Cardiaques Congénitales Complexes - M3C, Hôpital Necker-Enfants malades, Université de Paris, Paris.

Sophie Georgin-Lavialle (S)

S. Georgin-Lavialle, MD, PhD, AP-HP, Hôpital Tenon, Paris.

Gaëlle Guettrot-Imbert (G)

I. Miniaoui, MD, N. Morel, MD, K. Lévesque, MD, G. Guettrot-Imbert, MD, V. Le Guern, MD, L. Mouthon, MD, PhD, M. Jallouli, MD, AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris.

Véronique Le Guern (V)

I. Miniaoui, MD, N. Morel, MD, K. Lévesque, MD, G. Guettrot-Imbert, MD, V. Le Guern, MD, L. Mouthon, MD, PhD, M. Jallouli, MD, AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris.

Luc Mouthon (L)

I. Miniaoui, MD, N. Morel, MD, K. Lévesque, MD, G. Guettrot-Imbert, MD, V. Le Guern, MD, L. Mouthon, MD, PhD, M. Jallouli, MD, AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris.

Moez Jallouli (M)

I. Miniaoui, MD, N. Morel, MD, K. Lévesque, MD, G. Guettrot-Imbert, MD, V. Le Guern, MD, L. Mouthon, MD, PhD, M. Jallouli, MD, AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, Paris.

Christophe Deligny (C)

C. Deligny, MD, CHU Fort de France, Martinique.

Eric Hachulla (E)

E. Hachulla, MD, PhD, Université Lille, Inserm, CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), and U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille.

Bénédicte Romefort (B)

B. Romefort, Cardiopédiatrie, CHU de Nantes.

Damien Bonnet (D)

A. Maltret, MD, J. Le Bidois, MD, D. Bonnet, MD, PhD, AP-HP, Centre de référence Malformations Cardiaques Congénitales Complexes - M3C, Hôpital Necker-Enfants malades, Université de Paris, Paris.

Nathalie Costedoat-Chalumeau (N)

N. Costedoat-Chalumeau, MD, PhD, AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares d'Ile de France, and Université Paris Descartes-Sorbonne Paris Cité, and INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France. nathalie.costedoat@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH